Thymosin Beta-4: Evidence, Safety, Dosing, and Access

Thymosin beta-4, also called Tβ4 or TB4, is an actin-binding peptide studied in wound healing, dry eye, and cardiac repair. Its evidence grade is A because multiple human randomized trials are indexed in PubMed, but that does not prove it works or is safe for every use. Chia does not offer thymosin beta-4.

What it is

Thymosin beta-4 is a naturally occurring peptide, meaning a short chain of amino acids, found in many tissues. It is also written as thymosin β4, Tβ4, or TB4.

In simple terms, thymosin beta-4 is best known as an actin-sequestering peptide. Actin is a structural protein that helps cells keep their shape, move, and respond during repair. A review of beta-thymosins describes this actin-binding biology as central to the thymosin beta-4 research story 10.

Researchers have studied thymosin beta-4 in several settings, including venous ulcers, severe dry eye, corneal wounds, acute myocardial infarction, chronic ischemic heart failure, and human brain organoids used in Alzheimer disease research 1 4 5 8. These are research contexts, not proof that the peptide should be used broadly for healing, performance, or longevity; this article does not identify an FDA-approved thymosin beta-4 product for these uses.

Chia does not offer thymosin beta-4, TB4, or TB-500. If you are comparing peptides more broadly, our plain-language guides to TB4 peptide, TB-500, and peptides explained may help you sort the names before you make any health decision.

Names: thymosin beta-4, Tβ4, and TB4

Thymosin beta-4, thymosin β4, Tβ4, and TB4 usually refer to the same full-length peptide in the research literature. RGN-259 refers to an ophthalmic solution studied in eye disease trials, while NL005 refers to recombinant human thymosin beta-4 for injection in registered cardiac research 12 15.

Class: peptide

Thymosin beta-4 is a peptide, not a hormone like estrogen or progesterone and not a GLP-1 medication like semaglutide or tirzepatide. Peptides can act in many different ways, so one peptide’s evidence should not be used to judge another peptide without direct data.

Chia availability: education-only; Chia does not offer thymosin beta-4

At Chia, we treat patients online with treatments listed in our current catalog, but thymosin beta-4 is not one of them. That includes TB4 and TB-500. This page is here so patients can understand the science and avoid confusing research claims with personal medical advice.

Mechanism of action

Thymosin beta-4 is studied mainly because it binds actin, a protein that helps cells move, change shape, and take part in repair. The human mechanism is not fully established for every condition being studied, so many claimed effects remain proposed rather than proven.

What does actin-sequestering mean?

Actin-sequestering means thymosin beta-4 can bind actin building blocks and help regulate how actin is assembled inside cells. This is one reason researchers study it in cell movement, tissue remodeling, and repair biology 10.

That mechanism is biologically interesting, but it is not the same as showing that a product improves healing in people. For human use, the key question is always whether controlled human trials show benefit, what dose and route were tested, and what harms were seen.

Why researchers study it in wound healing, the eye, and cardiac repair

Researchers study thymosin beta-4 in wound and eye settings because cell movement and surface repair are important in ulcers, dry eye, and corneal injury. Human randomized studies have looked at venous ulcers and severe dry eye, but those findings should stay tied to those specific study settings 1 4 7.

Cardiac research is more complex. One randomized pilot study used autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST-segment elevation myocardial infarction, which is very different from a consumer injecting a peptide 2. Another study linked higher plasma Tβ4 after intracardiac cell therapy with symptomatic improvement in chronic ischemic heart failure, but that is an association in a specific cell-therapy context 5.

Evidence

Thymosin beta-4 has Evidence Grade A under the rubric below because at least 7 human randomized controlled trials are indexed in PubMed. That grade reflects the amount and design of evidence, not a guarantee that thymosin beta-4 works or is safe.

Venous ulcers

Two PubMed-indexed randomized reports studied thymosin beta-4 in venous ulcers. One described a European prospective randomized study focused on safety, tolerability, and enhancement of healing, and another reported the effect of thymosin treatment of venous ulcers 1 7.

These studies support saying thymosin beta-4 has been studied for venous ulcers. They do not support using it as a general wound-healing recommendation for cuts, tendon pain, sports injuries, or self-treatment.

Severe dry eye

A phase 2 randomized trial reported that thymosin β4 significantly improved signs and symptoms of severe dry eye 4. Registered trials also include RGN-259 ophthalmic solution studies for dry eye syndrome and neurotrophic keratitis, including a completed phase 2/3 dry-eye study listed with 317 participants and a recruiting phase 3 neurotrophic keratitis study listed with 70 participants 12 13.

That does not mean non-eye products sold online have the same evidence. Eye-drop research should not be applied to injectable, oral, nasal, or “research use only” products unless that exact product, route, and patient group were studied.

Healthy-volunteer safety studies

Human safety research includes a randomized placebo-controlled single- and multiple-dose study of intravenous thymosin beta4 in healthy volunteers 6. A first-in-human randomized, double-blind, single- and multiple-dose phase 1 study also tested recombinant human thymosin β4 in healthy Chinese volunteers 3.

Healthy-volunteer studies are useful for early safety signals, but they are limited. They usually cannot prove long-term safety, safety in people with major disease, or effectiveness for consumer goals like recovery or performance.

Cardiac repair and myocardial infarction research

A pilot randomized study evaluated autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST-segment elevation myocardial infarction 2. Registered research also includes recombinant human thymosin beta-4 for injection, NL005, in acute myocardial infarction 15.

These cardiac studies are not evidence for ordinary self-use. They involve hospital-level disease states, specialized products or cell therapy, and monitored research settings.

Brain organoids and Alzheimer disease research

A 2025 study identified thymosin beta 4 as a possible Alzheimer disease intervention target using human brain organoids 8. Brain organoids are lab models, not treated patients, so this is not evidence that thymosin beta-4 treats Alzheimer disease in humans.

What the evidence does not show

• It does not show that thymosin beta-4 extends human lifespan.
• It does not show that TB-500 products sold online have the same effects as thymosin beta-4 used in trials.
• It does not establish safe self-dosing for wound healing, sports recovery, or performance.
• It does not prove safety for pregnancy, breastfeeding, cancer history, immune disease, or complex heart disease.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-10.

Reported dosing ranges

Thymosin beta-4 dosing in this section means what was studied or listed in trial records, not what any reader should take. The supplied source records often do not provide enough dosing detail to create a patient dosing range.

Because the supplied records do not provide full dosing schedules for most settings, this page does not list a general dose. That is intentional: a dose in a venous-ulcer trial, eye-drop trial, or cardiac trial cannot be turned into a self-treatment plan.

Legal status

Our regulatory log holds no confirmed federal action for Thymosin Beta-4. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-10. See the full legal-status tracker for every compound we follow.

Safety

Thymosin beta-4 safety has been studied in healthy volunteers and in condition-specific trials, but the evidence is still limited by route, dose, product, and patient group. A healthy-volunteer trial cannot answer every safety question for people with wounds, eye disease, heart disease, immune conditions, or pregnancy 3 6.

What healthy-volunteer studies can and cannot tell us

The intravenous healthy-volunteer study and the recombinant human thymosin β4 phase 1 study help describe early tolerability under controlled research conditions 3 6. They do not prove long-term safety, safety across all routes, or safety of products made outside regulated medical channels.

Why trial setting, route, dose, and population matter

A peptide studied as an eye drop is not the same safety question as a peptide injected under the skin. A peptide used in cardiac cell therapy is not the same safety question as a product bought online for recovery. The cardiac studies were tied to specialized care settings, not ordinary consumer use 2 5.

Registered trials also show that some research was stopped before completion, including a phase 2 epidermolysis bullosa wound-healing study and a phase 2 corneal wound study 11 14. A trial listing shows research activity; it does not prove that the treatment is safe or effective.

Who should avoid thymosin beta-4 unless a clinician says otherwise?

• People with active heart disease or a recent heart event should not infer safety from cardiac research, because those studies involved monitored research settings 2 15.
• People with eye disease should not use non-prescribed eye products or substitute non-eye peptide products for ophthalmic research products studied in trials 4 13.
• People with active wounds, venous ulcers, diabetes-related wounds, or poor circulation should be evaluated by a clinician rather than self-treating, because ulcer studies do not create a general wound-care plan 1 7.
• People who are pregnant, breastfeeding, immunocompromised, or have a cancer history should be cautious because the supplied studies do not establish safety for those groups.
• Anyone considering a product labeled “research use only” should know that such material is not made for patient use and may raise identity, impurity, sterility, or contamination risks.

The supply source matters. Our peptide source guide explains why identity testing, sterility practices, and licensed medical oversight matter more than marketing claims. Our peptides online guide also explains why a website can look medical without being a licensed clinical channel.

Interactions

Thymosin beta-4 interaction studies are not clearly established in the supplied PubMed and trial records. That absence is not reassurance; it means patients should ask a clinician about their medications, diagnoses, and planned route before considering any peptide.

Medications, eye treatments, wound care, cardiac disease, pregnancy, and immune conditions

• Eye treatments: people using prescription eye drops, contact lenses, or treatment for corneal disease should not assume severe-dry-eye trial findings apply to other products 4 13.
• Wound care: people with ulcers or open wounds may need infection care, circulation testing, pressure relief, or diabetes care; venous-ulcer trials do not replace standard wound evaluation 1 7.
• Cardiac medications: people taking antiplatelet drugs, anticoagulants, blood-pressure medicines, or heart-failure medicines should discuss any peptide interest with a cardiology-aware clinician because cardiac studies used specialized research settings 2 5.
• Pregnancy and breastfeeding: the supplied records do not establish safety in pregnancy or breastfeeding.
• Immune conditions and cancer history: the supplied records do not establish safety for people with complex immune disease or cancer history.

How to obtain it legally

Thymosin beta-4 access should start with a licensed clinician evaluation, not self-treatment. A clinician can review your diagnosis, medications, pregnancy status, immune history, heart risk, eye disease, wound status, and goals before deciding whether any peptide discussion is appropriate.

A medical route generally means a real clinical evaluation, documentation, a prescription when clinically appropriate, and dispensing through a licensed pharmacy. A prescription is never guaranteed. A research-chemical website is not a clinician, not a diagnosis, and not a substitute for sterile medication prepared for patient use.

Chia does not offer thymosin beta-4, TB4, or TB-500. For treatments Chia does offer, care is 100% online: a short health questionnaire, licensed US provider review, provider-guided dosing when prescribed, US state-licensed 503A compounding pharmacy dispensing, and home delivery. Compounded drugs are not FDA-approved.

If your real goal is to understand peptide safety before making a decision, start with education. Useful next reads include TB-500 vs BPC-157, peptides explained, and how to find a legitimate peptide source.

FAQ

Keep reading

Peptides

TB-500: Evidence, Safety, Dosing, and Access

Peptides

Can You Buy TB-500 Peptide Online? What Patients Should Know

Peptides

BPC-157 Peptide: What It Is, What Research Shows, and Safety Risks